Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index must be between 17 kg/m\^2 and ≤ 33 kg/m\^2;~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use appropriate contraception;~* Males agree to use appropriate contraception;~* Diagnosis of TTR amyloidosis;~* Adequate blood counts, liver and renal function;~* Willing to give written informed consent and are willing to comply with the study requirements.~Exclusion Criteria:~* Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;~* Received an investigational agent, other than tafamidis or diflunisal, within 30 days prior to first dose study drug administration;~* Prior liver transplant;~* Poor cardiac function;~* Considered unfit for the study by the Principal Investigator;~* Employee or family member of the sponsor or the clinical study site personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patisiran (ALN-TTR02) (Type: EXPERIMENTAL): Two administrations of patisiran will be administered once every 4 weeks \[Q4W\]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks \[Q3W\]), and an alternative premedication regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).